Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 05, 2026
TickeronGET DAILY SIGNALS
Warby Parker (WRBY) Delivers Solid Q3 Results with +10.4% Revenue Growth and EPS Beat

Warby Parker (WRBY) Delivers Solid Q3 Results with +10.4% Revenue Growth and EPS Beat

Key Takeaways

  • Warby Parker reported third quarter 2026 revenue of $244.7 million, up 10.4% year over year and roughly in line with consensus estimates of about $244.9 million.
  • GAAP diluted earnings per share came in at $0.04, above the consensus estimate of $0.03.
  • Adjusted EBITDA reached $28.6 million, above guidance, with an adjusted EBITDA margin of 11.7%.
  • Active customers grew 3.0% to 2.74 million, while the company opened 12 net new stores to end the quarter with 364 locations.
  • Full-year revenue guidance was narrowed to 11% to 12% growth, now including a modest contribution from the upcoming Intelligent Eyewear launch.

Why This Quarter Matters

Warby Parker’s third quarter 2026 report carried particular weight because it arrived just ahead of the company’s first Intelligent Eyewear collection, developed in partnership with Google and Samsung. The vertically integrated eyewear retailer has been investing in stores, eye exams, and technology while facing softer traffic and an uneven optical environment. I was watching closely to see whether core business momentum could hold and whether profitability would stay intact ahead of that launch. The profitability beat, together with refined full-year guidance, offered a useful signal about the company’s ability to balance near-term execution with a longer-term growth bet on AI-powered glasses. I also checked this using Tickeron’s AI Screener to compare the stock with peers in the sector.

Breaking Down the Reported Results

For the third quarter ended September 30, 2026, Warby Parker reported net revenue of $244.7 million, a 10.4% increase from $221.7 million in the prior-year period. The result was essentially in line with, but fractionally below, analyst consensus of roughly $244.9 million. GAAP diluted EPS of $0.04 exceeded the consensus estimate of $0.03, while net income of $5.6 million slipped modestly from $5.9 million a year earlier.

Profitability showed resilience: gross margin improved to 54.4% from 54.1%, and adjusted EBITDA rose $2.8 million to $28.6 million, above the company’s guidance, with an adjusted EBITDA margin of 11.7%. Management highlighted disciplined execution even as selling, general, and administrative expenses increased, driven by retail compensation and technology costs. From what I see, the combination of an EPS beat and stronger adjusted EBITDA stands out as the key positive in the print.

Customer metrics also moved higher. Active customers increased 3.0% to 2.74 million on a trailing 12-month basis, while average revenue per customer rose 6.7% to $342. The company narrowed full-year revenue guidance to 11% to 12% growth, reflecting a modest contribution from Intelligent Eyewear deliveries late in the holiday window.

Market Reaction and Sentiment

The market responded enthusiastically to the report. According to third-party market data, WRBY shares jumped roughly 18.9% immediately after the release, a reaction driven less by the modest revenue in-line print and more by the profitability beat and the clearer picture of the Intelligent Eyewear rollout. Investors appeared to reward the combination of an EPS beat, adjusted EBITDA above guidance, and narrowed full-year revenue guidance that now incorporates early revenue from the new product category. Sentiment entering the report had been cautious following softer traffic trends and a slower pace of active customer growth, making the positive profit signals and the approaching product launch the central narrative for the stock.

Forward Outlook and Factors to Watch

Management’s updated outlook centers on the Intelligent Eyewear launch. Pre-orders were scheduled to begin on November 12, 2026, with initial customer deliveries expected by mid-December, positioning the category for a limited holiday contribution before a more meaningful ramp through 2027. Leadership has described 2027 as the start of a step-change growth opportunity as production and sales scale, backed by partnerships with Google and Samsung.

Investors will likely track several factors in the coming quarters. First is the pace of Intelligent Eyewear demand and delivery, since revenue is recognized when products reach customers rather than when orders are placed. Second is core business health, particularly retail traffic and active customer growth, which have been pressured by a softer consumer environment for cash-pay optical purchases. Third, the company’s store expansion remains a key driver, with roughly 50 net new openings planned for 2026. Finally, margins and cost discipline will matter as technology investments continue. The narrowing of full-year guidance, now including a modest Intelligent Eyewear contribution, gives investors a clearer baseline to assess whether the new category can accelerate growth into 2027. One thing that stands out is how the guidance update frames expectations for the new product line.

Refining Research with Tickeron Tools

I’ve found Tickeron’s AI Screener helpful for quickly filtering consumer discretionary names and spotting setups that share characteristics with WRBY. The tool lets me apply technical, fundamental, and performance criteria in one place, which speeds up the process of building a short list of comparable ideas before earnings season. It has become a regular part of my workflow when evaluating how a stock like this stacks up against peers.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: WRBY

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


WRBY sees MACD Histogram just turned negative

WRBY saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 26, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 52 instances where the indicator turned negative. In 46 of the 52 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on WRBY as a result. In 56 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.

WRBY moved below its 50-day moving average on October 26, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for WRBY crossed bearishly below the 50-day moving average on November 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.

The 50-day moving average for WRBY moved below the 200-day moving average on October 30, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where WRBY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +0.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where WRBY advanced for three days, in 227 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

WRBY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. WRBY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.714) is normal, around the industry mean (5.069). WRBY's P/E Ratio (354.833) is considerably higher than the industry average of (40.009). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (3.231) is also within normal values, averaging (56.876).

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WRBY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 9.91B. The market cap for tickers in the group ranges from 126 to 165.52B. ISRG holds the highest valuation in this group at 165.52B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was 0%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 12%. ZJYL experienced the highest price growth at 62%, while STVN experienced the biggest fall at -31%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 13%. For the same stocks of the Industry, the average monthly volume growth was 58% and the average quarterly volume growth was 7%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 58
P/E Growth Rating: 56
Price Growth Rating: 52
SMR Rating: 81
Profit Risk Rating: 93
Seasonality Score: 23 (-100 ... +100)
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsOther

Industry
N/A
Address
233 Spring Street
Phone
+1 646 847-7215
Employees
4036
Web
https://www.warbyparker.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
Xerox Holdings Corporation (XRX) stock price surged +114% over the past 30 days, driven primarily by a strong Q1 2026 revenue beat from the Lexmark acquisition. Over the past quarter, XRX is up +17%, recovering from mid-period lows amid volatile trading and financial concerns.
ExxonMobil reported GAAP net earnings of $4.2 billion, or $1.00 per diluted share (EPS), down from $7.7 billion, or $1.76 per share, in Q1 2025. Adjusted earnings excluding identified items reached $4.9 billion, or $1.16 per share, surpassing consensus estimates around $1.00 to $1.07.